SCHEMBL6136937

SCHEMBL6136937

COc1ccc(C(C)=O)c(Cl)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPT P10636 6/20 0.47
GAA P10253 1/20 0.47
HTT P42858 2/20 0.46
MAPK1 P28482 2/20 0.44
RAB9A P51151 2/20 0.44
S1PR4 O95977 1/20 0.44
HSP90AA1 P07900 1/20 0.44
G6PD P11413 1/20 0.44
S1PR1 P21453 1/20 0.44
OPRK1 P41145 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
MCL1 Q07820 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
TLR9 Q9NR96 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11251002 0.94 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL11251037 0.88 MAPT (0.47) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL11386183 0.86 MAPT (0.46) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL31697101 0.85 LMNA (0.47) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL31346670 0.85 MAPT (0.51) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL21822828 0.85 MAPT (0.49) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL4880989 0.85 ALDH1A1 (0.48) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL8135266 0.85 LMNA (0.47) ALDH1A1KDM4ELMNAHSD17B10MAPT
SCHEMBL6931814 0.84 TDP1 (0.55) ALDH1A1KDM4EHSD17B10MAPTHTT
SCHEMBL8492183 0.84 POLB (0.42) ALDH1A1KDM4ELMNAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111004107-B Substituted dichlorobenzene compound containing propenone, preparation method and application 山东大学 2021-03-16 CN disclosed
CN-111004107-A Substituted dichlorobenzene compound containing propenone, preparation method and application 山东大学 2020-04-14 CN disclosed
US-10407390-B2 Asymmetric ureas and medical uses thereof HELSINN HEALTHCARE SA 2019-09-10 US disclosed
US-20180044293-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2018-02-15 US disclosed
US-9751836-B2 Asymmetric ureas and medical uses thereof HELSINN HEALTHCARE SA (CH) 2017-09-05 US disclosed
EP-2678017-B1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2017-04-05 EP disclosed
US-8658797-B2 Asymmetric ureas and medical uses thereof HELSINN HEALTHCARE SA (CH) 2014-02-25 US disclosed
US-20120220629-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2012-08-30 US disclosed
WO-2012116176-A2 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2012-08-30 WO disclosed
WO-2012113103-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE S.A. (CH) 2012-08-30 WO disclosed
EP-1556038-A2 ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2005-07-27 EP disclosed
EP-1011651-B1 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES MERCK & CO INC (US) 2005-04-27 EP disclosed
WO-2004018386-A2 ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2004-03-04 WO disclosed
EP-1011651-A1 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES Merck & Co., Inc. (US) 2000-06-28 EP disclosed
EP-1011651-A4 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES MERCK & CO INC (US) 2000-06-28 EP disclosed
US-6020382-A Method of treating diabetes and related disease states MERCK & CO., INC. (US) 2000-02-01 US disclosed
US-5847008-A Method of treating diabetes and related disease states MERCK & CO., INC. (US) 1998-12-08 US disclosed
WO-1997027847-A1 METHOD OF TREATING DIABETES AND RELATED DISEASE STATES MERCK & CO., INC. (US) 1997-08-07 WO disclosed
EP-0106565-B1 LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM MERCK FROSST CANADA INC. (CA) 1986-09-10 EP disclosed
EP-0106565-A1 Leukotriene antagonists, their production, and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220629-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF UTS2R, GPR119, GHSR ALDH1A1 1976/4885KDM4E 3883/4885LMNA 3368/4885
US-10407390-B2 Asymmetric ureas and medical uses thereof UTS2R, GPR119, GHSR ALDH1A1 1976/4885KDM4E 3883/4885LMNA 3368/4885
US-20180044293-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF UTS2R, GPR119, GHSR ALDH1A1 1976/4885KDM4E 3883/4885LMNA 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.